Skip to main content
Premium Trial:

Request an Annual Quote

Physiome Licenses PathwayPrism Technology to 3rd Millennium

NEW YORK, Aug. 28 – Physiome Sciences has licensed its PathwayPrism modeling technology to 3rd Millennium to help it develop products for Huntington’s disease, the companies said on Tuesday.

The deal will allow Cambridge, Mass.-based 3rd Millennium and its academic partners “to visualize and stimulate pathways” involved in the disease, the companies said in a statement.

“We chose Physiome’s technology after a thorough review because it represents the best method for building, visualizing, and stimulating disease pathways like Huntington’s,” Richard Dweck, president of 3rd Millennium, said in the statement.

Financial terms of the licensing agreement were not disclosed, and representatives from either company were not immediately available for comment.

3rd Millennium, a privately held firm that develops life science-based information systems, will combine its deal with Physiome with its newly developed data integration technology.

This technology, which was paid for in part through a two-year, $1.8 million Advanced Technology Program grant, has been designed to store and integrate many types of biologic data along with their biological content, the companies said. This provides computer models that combine “context of organs, tissues, and cells with gene expression, interaction, and functional data,” they added.

Huntington’s disease, a fatal, autosomal-dominant neurological disease that causes psychosis and dyskinesia, was chosen because of the amount of publicly available data about it, the companies said.

Last week, IBM and Physiome, of Princeton, NJ, entered into a non-exclusive alliance that would combine IBM's supercomputing technology with Physiome’s biological modeling software.  

The deal , which makes IBM Physiome's preferred IT supplier for custom computing, will allow Physiome to “speed up” its ability to simulate models of various cells, tissues and organs, and affect the behavior of certain disease states. 

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.